Pharmaceutical Benefits Scheme (PBS) prescription—therapeutic group, code N
Identifying and definitional attributes | |
Metadata item type: | Data Element |
|---|---|
| Short name: | Therapeutic group |
| METEOR identifier: | 605587 |
| Registration status: |
|
| Definition: | A narrowly defined group of drugs listed in the Schedule of Pharmaceutical Benefits that are of similar safety and efficacy and provide similar health outcomes, as represented by a code. |
| Context: | Therapeutic groups are defined for the purpose of comparative pricing. The government subsidises all drugs within a therapeutic group up to the level of the lowest priced drug. Any difference between the subsidised price and the price of the drug used by the patient is called the 'therapeutic group premium' and is paid by the patient. |
| Data Element Concept: | Pharmaceutical Benefits Scheme (PBS) prescription—therapeutic group |
Value domain attributes | |||||||||||||||
Representational attributes | |||||||||||||||
| Representation class: | Code | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Data type: | Number | ||||||||||||||
| Format: | N | ||||||||||||||
| Maximum character length: | 1 | ||||||||||||||
| Permissible values: |
| ||||||||||||||
| Supplementary values: |
| ||||||||||||||
Collection and usage attributes | |||||||||||||||
| Guide for use: | Due to the number of changes to the lists of drugs included in the various therapeutic groups, this value domain is only suitable for use in relation to data for part or all of the 2013-14 financial year. The Permissible values in this value domain equate to Part numbers in the relevant Determination describing each therapeutic group and the drugs included in each therapeutic group, i.e. the National Health (Pharmaceutical Benefits—Therapeutic Groups) Determination 2010 (PB 1 of 2010) (Cwth). CODE 1 Angiotensin converting enzyme (ACE) inhibitor group This group includes the following listed drugs:
NOTE: This therapeutic group was removed from the therapeutic groups listed in the Determination by amendment PB 47 of 2013, effective from 1 August 2013. CODE 2 Angiotensin II receptor antagonist (ATRA) group This group includes the following listed drugs:
CODE 4 H2 receptor antagonist (H2RA) group This group includes the following listed drugs:
CODE 5 Proton pump inhibitor (PPI) group This group includes the following listed drugs:
NOTE: Rabeprazole was removed from this therapeutic group, as listed in the Determination, by amendment PB 23 of 2014, effective from 1 April 2014. CODE 7 Statins-HP group This group includes the following listed drugs:
NOTE: Atorvastatin was removed from this therapeutic group, as listed in the Determination, by amendment PB 77 of 2013, effective from 1 December 2013. CODE 8 Venlafaxine group This group includes the following listed drugs:
NOTE: Venlafaxine was removed from this therapeutic group, as listed in the Determination, by amendment PB 77 of 2013, effective from 1 December 2013. | ||||||||||||||
| Comments: | This value domain retains the relevant permissible values, i.e. Part numbers from within the Determination, from previous versions to ensure consistency across versions. | ||||||||||||||
Source and reference attributes | |||||||||||||||
| Submitting organisation: | Department of Health | ||||||||||||||
| Reference documents: | Office of Parliamentary Counsel, ComLaw website 2013. National Health (Pharmaceutical Benefits—Therapeutic Groups) Determination 2010 (PB 1 of 2010), including amendments up to PB 6 and 7 of 2013. Office of Parliamentary Counsel, Canberra. Viewed 17 November 2015, Office of Parliamentary Counsel, ComLaw website 2013. National Health (Pharmaceutical Benefits - Therapeutic Groups) Amendment Determination 2013 (No. 3) (PB No. 47 2013). Office of Parliamentary Counsel, Canberra. Viewed 17 November 2015, Office of Parliamentary Counsel, ComLaw website 2013. National Health (Pharmaceutical Benefits—Therapeutic Groups) Determination 2010 (PB 1 of 2010), including amendments up to PB 47 of 2013. Office of Parliamentary Counsel, Canberra. Viewed 17 November 2015, Office of Parliamentary Counsel, ComLaw website 2013. National Health (Pharmaceutical Benefits - Therapeutic Groups) Amendment Determination 2013 (No. 4) (PB No. 77 2013). Office of Parliamentary Counsel, Canberra. Viewed 17 November 2015, Office of Parliamentary Counsel, ComLaw website 2013. National Health (Pharmaceutical Benefits—Therapeutic Groups) Determination 2010 (PB 1 of 2010), including amendments up to PB 77 of 2013. Office of Parliamentary Counsel, Canberra. Viewed 17 November 2015, Office of Parliamentary Counsel, ComLaw website 2014. National Health (Pharmaceutical Benefits - Therapeutic Groups) Amendment Determination 2014 (No. 1) (PB No. 23 2014). Office of Parliamentary Counsel, Canberra. Viewed 17 November 2015, Office of Parliamentary Counsel, ComLaw website 2014. National Health (Pharmaceutical Benefits—Therapeutic Groups) Determination 2010 (PB 1 of 2010), including amendments up to PB 23 of 2014. Office of Parliamentary Counsel, Canberra. Viewed 17 November 2015, | ||||||||||||||
Data element attributes | |||||||||||||||
Collection and usage attributes | |||||||||||||||
| Guide for use: | Drugs listed within a therapeutic group are therapeutically interchangeable with other drugs in the same group. | ||||||||||||||
Source and reference attributes | |||||||||||||||
| Submitting organisation: | Department of Health | ||||||||||||||
Relational attributes | |||||||||||||||
| Implementation in Data Set Specifications: All attributes + |
| ||||||||||||||